Oppenheimer raised the firm’s price target on Pharvaris (PHVS) to $50 from $44 and keeps an Outperform rating on the shares. The firm notes the company reported positive top-line results for the pivotal RAPIDe-3, study of deucrictibant in the on-demand setting, hitting statistical significance across all primary and secondary endpoints. This result is a clear win for Pharvaris in the on-demand setting where it will compete with Kalvista’s (KALV) recently launched Ekterly, with positive read-across to deucrictibant in the larger prophylactic setting, with those pivotal results anticipated in the second half of 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris price target raised to $39 from $32 at Guggenheim
- Pharvaris’s Deucrictibant: Promising Efficacy Amidst Uncertain Market Prospects
- Pharvaris price target raised to $30 from $27 at BofA
- Pharvaris price target raised to $41 from $37 at Morgan Stanley
- Pharvaris’ Deucrictibant Shows Promising Efficacy and Safety in RAPIDe-3 Study, Analyst Sets Buy Rating with Increased Price Target